|Bid||9.97 x 800|
|Ask||9.97 x 2200|
|Day's range||9.38 - 10.71|
|52-week range||0.25 - 15.69|
|Beta (5Y monthly)||2.37|
|PE ratio (TTM)||N/A|
|Earnings date||12 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.94|
Bionano Genomics (NASDAQ: BNGO) has certainly created a buzz in 2021. It's one of the top 100 most-popular stocks on Robinhood. Bionano's shares have skyrocketed more than 340% so far this year.
If you don't have an answer to this (large, open-ended, highly technical) question, don't worry: BioNano Genomics (NASDAQ: BNGO) might. As its name implies, the company makes laboratory equipment that helps researchers and clinicians answer a narrow subset of those thorny genomics questions. BioNano's Saphyr genome mapping device detects large structural variations and aberrations in chromosomes, which is something that standard gene sequencers can't do.
What happened Shares of Bionano Genomics (NASDAQ: BNGO) hit a record high on Friday. By the close of trading, the genome analysis company's stock price was up 17%. So what On Thursday, Bionano Genomics released a study showing that its Saphyr optical genome mapping (OGM) system could be used to analyze a wide variety of solid tumors in cancer research.